763113-22-0 | Olaparib

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$9.00	$6.00
250mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$22.00	$15.00
5g	98%	in stock	$93.00	$65.00
10g	98%	in stock	$162.00	$113.00
100g	98%	in stock	$1,317.00	$922.00

Description

• Catalog Number: AB48261
• Chemical Name: Olaparib
• CAS Number: 763113-22-0
• Molecular Formula: C24H23FN4O3
• Molecular Weight: 434.4628
• MDL Number: MFCD13185161
• SMILES: O=C(N1CCN(CC1)C(=O)c1cc(ccc1F)Cc1n[nH]c(=O)c2c1cccc2)C1CC1
• NSC Number: 747856

Computed Properties

• Complexity: 790
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 1.9

Upstream Synthesis Route

The compound 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine is a versatile molecule with significant applications in chemical synthesis. In organic synthesis, this compound can be utilized as a key building block for the creation of various pharmaceuticals, agrochemicals, and functional materials. Its unique structure provides opportunities for introducing specific functional groups and stereochemistry into target molecules, making it a valuable tool in the development of new chemical entities. The piperazine moiety in this compound also offers the potential for interactions with biological targets, further enhancing its utility in drug discovery and development. By incorporating 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine into synthetic routes, chemists can access diverse compound libraries and advance the field of medicinal chemistry.

Literature

• Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

  Nature genetics 20180801

• An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.

  BMC cancer 20160101

• 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53.

  Oncotarget 20151222

• PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.

  Molecular cancer therapeutics 20151201

• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  The New England journal of medicine 20151029

• Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

  Journal of medicinal chemistry 20150910

• Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20150401

• Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.

  Cell metabolism 20140603

• Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

  Nature reviews. Drug discovery 20140601

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  Cancer discovery 20130101

• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  Cancer research 20121101

• Olaparib, PARP1 inhibitor in ovarian cancer.

  Expert opinion on investigational drugs 20121001

• Clinical trials and future potential of targeted therapy for ovarian cancer.

  International journal of clinical oncology 20121001

• Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

  EMBO molecular medicine 20121001

• [Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20121001

• Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

  Current opinion in oncology 20120901

• Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

  Breast cancer research and treatment 20120901

• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  Cancer discovery 20120901

• Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

  Investigational new drugs 20120801

• Neoadjuvant treatments for triple-negative breast cancer (TNBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Olaparib in platinum-sensitive ovarian cancer.

  The New England journal of medicine 20120712

• Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.

  Breast cancer research and treatment 20120701

• BAP1 loss defines a new class of renal cell carcinoma.

  Nature genetics 20120701

• Current and emerging targeted therapies for metastatic breast cancer.

  Cancer 20120615

• Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

  Hepatology (Baltimore, Md.) 20120601

• Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

  EMBO molecular medicine 20120601

• A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  The New England journal of medicine 20120412

• PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

  Cancer research 20120401

• A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

  The oncologist 20120401

• [PARP inhibitors and breast cancer: update and perspectives].

  Bulletin du cancer 20120401

• Drug candidates derailed in case of mistaken identity.

  Nature 20120328

• Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

  Cancer science 20120301

• Synthetic lethality of cohesins with PARPs and replication fork mediators.

  PLoS genetics 20120301

• Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.

  Neoplasia (New York, N.Y.) 20120301

• Present status and problems on molecular targeted therapy of cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20120301

• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.

  Nature biotechnology 20120219

• Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.

  Molecular cell 20120210

• Structural basis of selective inhibition of human tankyrases.

  Journal of medicinal chemistry 20120209

• Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201

• Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

  British journal of cancer 20120131

• Basal breast cancer: a complex and deadly molecular subtype.

  Current molecular medicine 20120101

• Ovarian cancer: opportunity for targeted therapy.

  Journal of oncology 20120101

• BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

  PloS one 20120101

• Molecular basis of triple negative breast cancer and implications for therapy.

  International journal of breast cancer 20120101

• Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.

  International journal of breast cancer 20120101

• Therapeutic strategies in epithelial ovarian cancer.

  Journal of experimental & clinical cancer research : CR 20120101

• Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

  PloS one 20120101

• Major clinical research advances in gynecologic cancer in 2011.

  Journal of gynecologic oncology 20120101

• Advances in using PARP inhibitors to treat cancer.

  BMC medicine 20120101

• Novel binding mode of a potent and selective tankyrase inhibitor.

  PloS one 20120101

• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

  Journal of oncology 20120101

• Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.

  PloS one 20120101

• Brain metastases from endometrial carcinoma.

  ISRN oncology 20120101

• The combination of olaparib and camptothecin for effective radiosensitization.

  Radiation oncology (London, England) 20120101

• Combination drug delivery approaches in metastatic breast cancer.

  Journal of drug delivery 20120101

• Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.

  PloS one 20120101

• The first European interdisciplinary ewing sarcoma research summit.

  Frontiers in oncology 20120101

• Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

  Anemia 20120101

• Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.

  PloS one 20120101

• Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

  Cell cycle (Georgetown, Tex.) 20111215

• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

  Current drug targets 20111201

• Update on PARP1 inhibitors in ovarian cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.

  Oncotarget 20111201

• Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

  Nuclear medicine communications 20111101

• BRCA1 and BRCA2 mutations and breast cancer.

  Discovery medicine 20111101

• Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

  Journal of clinical pathology 20111001

• Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

  Molecular cancer therapeutics 20111001

• PARP inhibitors--current status and the walk towards early breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• Functional characterization of EMSY gene amplification in human cancers.

  The Journal of pathology 20110901

• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  The Lancet. Oncology 20110901

• Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110701

• Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  The Journal of clinical investigation 20110701

• Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

  Nature medicine 20110701

• PARP inhibitors: its role in treatment of cancer.

  Chinese journal of cancer 20110701

• The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.

  PLoS genetics 20110701

• Epistatic relationships in the BRCA1-BRCA2 pathway.

  PLoS genetics 20110701

• Novel agents and future directions for refractory breast cancer.

  Seminars in oncology 20110601

• Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

  Nature reviews. Clinical oncology 20110501

• 5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).

  Journal of medicinal chemistry 20110414

• MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

  The Journal of biological chemistry 20110408

• A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

  British journal of cancer 20110301

• Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.

  Angewandte Chemie (International ed. in English) 20110218

• Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

• Characteristics of triple-negative breast cancer.

  Journal of cancer research and clinical oncology 20110201

• 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.

  Current opinion in obstetrics & gynecology 20110201

• Triple negative breast cancer: unmet medical needs.

  Breast cancer research and treatment 20110201

• Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

  Virchows Archiv : an international journal of pathology 20110101

• Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.

  Genome integrity 20110101

• Breast cancer genome heterogeneity: a challenge to personalised medicine?

  Breast cancer research : BCR 20110101

• PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

  Acta clinica Belgica 20110101

• Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

  Journal of hematology & oncology 20110101

• BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• Concordant and opposite roles of DNA-PK and the 'facilitator of chromatin transcription' (FACT) in DNA repair, apoptosis and necrosis after cisplatin.

  Molecular cancer 20110101

• Targeted therapy in breast cancer: what's new?

  Swiss medical weekly 20110101

• Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

  Cancer management and research 20110101

• Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

  BMC pharmacology 20110101

• Rare variants in the ATM gene and risk of breast cancer.

  Breast cancer research : BCR 20110101

• Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

  PloS one 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Management options in triple-negative breast cancer.

  Breast cancer : basic and clinical research 20110101

• Genetic dissection of PARylation in the filamentous fungus Neurospora crassa.

  Methods in molecular biology (Clifton, N.J.) 20110101

• Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

  Breast cancer research : BCR 20110101

• Platinum resistance in breast and ovarian cancer cell lines.

  Journal of experimental & clinical cancer research : CR 20110101

• MicroRNAs associated with metastatic prostate cancer.

  PloS one 20110101

• A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

  BMC medical genetics 20110101

• Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

  BMC medical genomics 20110101

• Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.

  PloS one 20110101

• Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

  PloS one 20110101

• Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.

  International journal of surgical oncology 20110101

• Triple-negative breast cancer: adjuvant therapeutic options.

  Chemotherapy research and practice 20110101

• Multidrug resistance in breast cancer: from in vitro models to clinical studies.

  International journal of breast cancer 20110101

• Therapeutic targeting of cancer stem cells.

  Frontiers in oncology 20110101

• BRCA mutations in the management of breast cancer: the state of the art.

  Nature reviews. Clinical oncology 20101201

• [PARP inhibitors to treat triple negative breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

  Blood 20101125

• Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

  British journal of cancer 20101109

• Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

  Cellular and molecular life sciences : CMLS 20101101

• Molecule of the month. Olaparib.

  Drug news & perspectives 20101101

• Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.

  Nature structural & molecular biology 20101001

• Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.

  Nature reviews. Clinical oncology 20101001

• Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.

  PLoS genetics 20101001

• PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

  Current opinion in oncology 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.

  Journal of the National Cancer Institute 20100804

• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  Lancet (London, England) 20100724

• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  Lancet (London, England) 20100724

• [Treatment with oral agents for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.

  IDrugs : the investigational drugs journal 20100601

• Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.

  Molecular cancer therapeutics 20100601

• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520

• Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.

  Yonsei medical journal 20100501

• Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

  Cancer research 20100215

• ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

  Molecular cancer therapeutics 20100201

• A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.

  Journal of oncology 20100101

• A current review of targeted therapeutics for ovarian cancer.

  Journal of oncology 20100101

• Targeted therapies in epithelial ovarian cancer.

  Journal of oncology 20100101

• Targeted therapy in ovarian cancer.

  Journal of oncology 20100101

• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

  Breast cancer research : BCR 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Biology-driven cancer drug development: back to the future.

  BMC biology 20100101

• Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.

  Cancer journal (Sudbury, Mass.) 20100101

• Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

  Breast cancer research : BCR 20100101

• Does race affect outcomes in triple negative breast cancer?

  Breast cancer : basic and clinical research 20100101

• Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

  BMC cancer 20100101

• PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

  F1000 biology reports 20100101

• Treatment options for patients with triple-negative breast cancer.

  Journal of hematology & oncology 20100101

• Present and future evolution of advanced breast cancer therapy.

  Breast cancer research : BCR 20100101

• Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

  Breast cancer research : BCR 20100101

• Triple-negative breast cancer.

  Breast cancer research : BCR 20100101

• Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

  Breast cancer research : BCR 20100101

• Are current development programs realising the full potential of new agents?

  Breast cancer research : BCR 20100101

• New developments in treatment of ovarian carcinoma: focus on trabectedin.

  Cancer management and research 20100101

• Preclinical mouse models for BRCA1-associated breast cancer.

  British journal of cancer 20091117

• Converting cancer mutations into therapeutic opportunities.

  EMBO molecular medicine 20090901

• Triple-negative breast cancer: novel therapies and new directions.

  Maturitas 20090820

• Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

  Cancer cell 20090804

• Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.

  Molecular cancer therapeutics 20090801

• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  The New England journal of medicine 20090709

• Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

  Cancer research 20090501

• Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

  Breast cancer research : BCR 20090101

• BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

  Journal of ovarian research 20090101

• Synthetic lethality: a framework for the development of wiser cancer therapeutics.

  Genome medicine 20090101

• PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? The scenario.

  Breast cancer research : BCR 20090101

• Tailored targeted therapy for all: a realistic and worthwhile objective?

  Breast cancer research : BCR 20090101

• Recent advances in managing triple-negative breast cancers.

  F1000 medicine reports 20090101

• Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

  International journal of radiation oncology, biology, physics 20081115

• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

  Proceedings of the National Academy of Sciences of the United States of America 20081104

• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  Journal of medicinal chemistry 20081023

• A FlashPlate assay for the identification of PARP-1 inhibitors.

  Journal of biomolecular screening 20030601